Earnings summaries and quarterly performance for Avantor.
Executive leadership at Avantor.
Emmanuel Ligner
Detailed
President and Chief Executive Officer
CEO
BG
Benoit Gourdier
Detailed
Executive Vice President, Bioscience Production
BJ
Brent Jones
Detailed
Executive Vice President and Chief Financial Officer
CS
Claudius Sokenu
Detailed
Executive Vice President, Chief Legal and Compliance Officer
JB
James Bramwell
Detailed
Executive Vice President, Sales and Customer Excellence
Board of directors at Avantor.
GL
Gregory Lucier
Detailed
Director
GS
Gregory Summe
Detailed
Director
JC
John Carethers
Detailed
Director
JP
Jonathan Peacock
Detailed
Chairman of the Board
JM
Joseph Massaro
Detailed
Director
JA
Juan Andres
Detailed
Director
LK
Lan Kang
Detailed
Director
LM
Louise Makin
Detailed
Director
MM
Mala Murthy
Detailed
Director
MS
Michael Severino
Detailed
Director
Research analysts who have asked questions during Avantor earnings calls.
Luke Sergott
Barclays
8 questions for AVTR
Also covers: A, BRKR, CERT +20 more
Michael Ryskin
Bank of America Merrill Lynch
8 questions for AVTR
Also covers: A, ALGN, BRKR +29 more
Vijay Kumar
Evercore ISI
8 questions for AVTR
Also covers: A, ABT, AZTA +23 more
Daniel Brennan
TD Cowen
6 questions for AVTR
Also covers: A, ADPT, BDSX +25 more
Tycho Peterson
Jefferies
6 questions for AVTR
Also covers: A, BIO, BLLN +22 more
Patrick Donnelly
Citi
5 questions for AVTR
Also covers: A, BIO, BRKR +24 more
Douglas Schenkel
Wolfe Research, LLC
3 questions for AVTR
Also covers: A, BRKR, DHR +21 more
Doug Schenkel
Wolfe Research LLC
3 questions for AVTR
Also covers: A, BRKR, DHR +19 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for AVTR
Also covers: A, ADPT, AKYA +14 more
TS
Tejas Savant
Morgan Stanley
3 questions for AVTR
Also covers: ADPT, AKYA, CRL +19 more
Brandon Couillard
Wells Fargo & Company
2 questions for AVTR
Also covers: A, BIO, BRKR +10 more
CW
Casey Woodring
JPMorgan Chase & Co.
2 questions for AVTR
Also covers: A, BLLN, CRL +15 more
CN
Conor Noel McNamara
RBC Capital Markets
2 questions for AVTR
Also covers: BIO, HOLX, ILMN +6 more
DB
Dan Brennan
UBS
2 questions for AVTR
Also covers: A, ADPT, BRKR +17 more
DL
Dan Leonard
UBS Group AG
2 questions for AVTR
Also covers: A, BIO, DHR +13 more
ML
Matt Larew
William Blair & Co.
2 questions for AVTR
Also covers: AMED, ATR, MRVI +10 more
Paul Knight
KeyBanc Capital Markets
2 questions for AVTR
Also covers: A, ATR, AZTA +16 more
BC
Brandon Couillard
Wells Fargo
1 question for AVTR
Also covers: A, BLLN, BRKR +4 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for AVTR
Also covers: A, CDXS, DHR +15 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for AVTR
Also covers: A, BIO, CRL +15 more
Jack Meehan
Nephron Research LLC
1 question for AVTR
Also covers: A, BIO, CARS +18 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
1 question for AVTR
Also covers: A, ADPT, CRL +21 more
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for AVTR
Also covers: A, AKYA, CARS +11 more
Recent press releases and 8-K filings for AVTR.
Avantor Announces Q4 & FY 2025 Earnings and FY 2026 Guidance
AVTR
Earnings
Guidance Update
M&A
- Avantor reported Q4 2025 revenue of $1,664 million and Adjusted EPS of $0.22, with FY 2025 revenue reaching $6,552 million and Adjusted EPS of $0.90.
- For fiscal year 2025, the company experienced -3% organic growth and generated $496 million in Free Cash Flow.
- The company issued full year 2026 guidance, forecasting organic revenue growth between -2.5% and -0.5%, an Adjusted EBITDA margin of 14.8% to 15.3%, and Adjusted EPS in the range of $0.77 to $0.83.
- Avantor is implementing a "Revival" initiative and has introduced new segment structures, VWR Distribution & Services and Bioscience & Medtech Products, following the divestiture of the Clinical Services business which resulted in a ~$150 million headwind to FY25 Revenue.
Feb 11, 2026, 1:00 PM
Avantor Reports Q4 and Full-Year 2025 Results, Announces Strategic Resegmentation and 2026 Guidance
AVTR
Earnings
Guidance Update
New Projects/Investments
- Avantor reported Q4 2025 revenue of $1.66 billion, a 4% organic decline year-over-year, and full-year 2025 revenue of $6.552 billion, down 3% organically. Adjusted EPS was $0.22 for Q4 and $0.90 for the full year.
- The company launched "Project Revival" to sharpen strategic focus and improve execution, leading to a resegmentation of the business into VWR Distribution and Services and Bioscience and Medtech Products, effective Q1 2026.
- For 2026, Avantor expects organic revenue growth of -2.5% to -0.5% and anticipates EBITDA margins to contract by 100-150 basis points due to investments and other factors. Q1 2026 is projected to be the low point for financial metrics, with organic revenues declining by 5% or more.
- In Q4 2025, Avantor purchased $75 million of stock, paid down approximately $300 million of debt, and added approximately $120 million of cash to the balance sheet, ending the quarter with adjusted net leverage of 3.2 times adjusted EBITDA.
Feb 11, 2026, 1:00 PM
Avantor Announces Q4 2025 Results and 2026 Guidance with Strategic Reorganization
AVTR
Guidance Update
New Projects/Investments
Demand Weakening
- Avantor launched "Project Revival" and reorganized into two new reporting segments effective Q1 2026: VWR Distribution and Services (72% of 2025 revenue, 11.5% adjusted operating margin) and Bioscience and Medtech Products (28% of 2025 revenue, 26.7% adjusted operating margin).
- For fiscal year 2026, Avantor expects organic revenue growth of -2.5% to -0.5% and reported revenue growth of -1.5% to +0.5%.
- The company anticipates 2026 adjusted EBITDA margins to contract by 100-150 basis points and projects adjusted EPS to be between $0.77 and $0.83, with Q1 2026 EPS expected at $0.15-$0.16 as the low point for the year.
- Avantor expects to generate $500 million to $550 million in free cash flow in 2026, characterizing the year as one of "transition and investment" to strengthen the business.
Feb 11, 2026, 1:00 PM
Avantor Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Announces Business Resegmentation
AVTR
Earnings
Guidance Update
New Projects/Investments
- Avantor reported Q4 2025 revenue of $1.66 billion, a 4% organic decline, and full-year 2025 revenue of $6.552 billion, a 3% organic decline, with adjusted EPS of $0.22 for Q4 and $0.90 for the full year.
- For 2026, the company forecasts organic revenue growth of -2.5% to -0.5% and adjusted EPS between $0.77 and $0.83, expecting EBITDA margins to contract by 100-150 basis points due to investments and other factors.
- The company is implementing "Project Revival," resegmenting its business into VWR Distribution and Services and Bioscience and Medtech Products effective Q1 2026, and recommitting to the VWR brand.
- Avantor plans significant investments in 2026, including $10 million-$15 million for e-commerce upgrades and $20 million to enhance operations, while prioritizing debt reduction to achieve leverage sustainably below 3 times net debt to Adjusted EBITDA.
Feb 11, 2026, 1:00 PM
Avantor Reports Q4 and Full Year 2025 Results
AVTR
Earnings
Demand Weakening
New Projects/Investments
- Avantor reported net sales of $1.66 billion for the fourth quarter of 2025, a 1% decrease, and $6.55 billion for the full year 2025, a 3% decrease.
- For Q4 2025, the company achieved net income of $52 million and adjusted EPS of $0.22, while for the full year 2025, it reported a net loss of $530 million and adjusted EPS of $0.90.
- The company initiated a "Revival program" in Q4 2025, which includes relaunching the VWR brand, implementing critical manufacturing and supply chain improvements, and upgrading its e-commerce channel, with 2026 expected to be a year of transition and purposeful investment to drive top-line growth.
Feb 11, 2026, 12:40 PM
Avantor Reports Fourth Quarter and Full Year 2025 Results
AVTR
Earnings
Demand Weakening
New Projects/Investments
- Avantor reported net sales of $1.66 billion for the fourth quarter of 2025, a 1% decrease with an organic decrease of 4%.
- For the full year 2025, net sales were $6.55 billion, a 3% decrease with an organic decline of 3%.
- The company reported a net income of $52 million and adjusted EPS of $0.22 for Q4 2025, while the full year 2025 saw a net loss of $530 million and adjusted EPS of $0.90.
- Avantor is implementing a "Revival program" focused on relaunching the VWR brand, improving manufacturing and supply chain, and upgrading its e-commerce channel, with 2026 expected to be a year of transition and purposeful investment.
Feb 11, 2026, 11:05 AM
Avantor faces investigation for alleged breaches of fiduciary duty
AVTR
Legal Proceedings
Demand Weakening
- Johnson Fistel, PLLP is investigating Avantor, Inc. (NYSE: AVTR) officers and directors for alleged breaches of fiduciary duty.
- The investigation is based on a previously filed federal securities class action complaint alleging that Avantor made materially false and misleading statements and/or failed to disclose material adverse facts concerning its business, operations, and prospects.
- The complaint specifically alleges that Avantor’s competitive positioning was weaker than publicly represented and that the company was experiencing negative effects from increased competition.
- Shareholders who have held Avantor shares continuously since prior to March 5, 2024, may have standing to seek corporate governance reforms.
Feb 5, 2026, 3:50 PM
Avantor Management Discusses Revival Program, Strategic Initiatives, and Financial Commitments at J.P. Morgan Conference
AVTR
New Projects/Investments
Share Buyback
Guidance Update
- Avantor's CEO, Emmanuel Ligner, who joined in August 2025, launched the Revival program in October 2025, a strategic initiative focused on enhancing go-to-market, improving manufacturing and supply chain, refocusing the portfolio, driving cost out, and strengthening talent.
- The company plans significant investments, including $10-$15 million in 2026 for its e-commerce platform and $20 million for manufacturing equipment to enhance reliability.
- Avantor is committed to reducing debt and leverage below 3.1 (from 3.1 at the end of Q3 2025) and has authorized a $500 million share buyback to be executed opportunistically without increasing leverage.
- The company will release its Q4 performance and 2026 guidance on February 11, 2026.
Jan 14, 2026, 4:15 PM
Navantor Presents Revival Plan and Capital Allocation Priorities at J.P. Morgan Healthcare Conference
AVTR
New Projects/Investments
Share Buyback
Management Change
- Navantor (AVTR) presented its "Revival" plan at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, outlining strategies for performance improvement through strategic investments, portfolio optimization, and talent strengthening.
- As part of its strategic investments, the company plans to invest ~$20M in 2026 to replace aging equipment in its manufacturing and supply chain organization.
- Near-term capital allocation priorities are focused on debt repayment and opportunistic share repurchase, with an Adjusted Net Leverage of 3.1x as of Q3 2025 and a $500M Share purchase authorization.
- Recent management changes include the appointment of Mary Blenn to the newly-created COO role and an Investor Relations leader starting February 1.
Jan 14, 2026, 4:15 PM
Avantor Outlines "Revival Program" and Financial Priorities at J.P. Morgan Healthcare Conference
AVTR
New Projects/Investments
Share Buyback
Guidance Update
- Avantor launched a "Revival program" in October, focusing on enhancing go-to-market strategy, improving manufacturing and supply chain, refocusing its portfolio, driving cost savings, and strengthening talent.
- The company plans to invest $10-$15 million in 2026 to revamp its e-commerce platform and approximately $20 million in manufacturing equipment to enhance reliability.
- Avantor is committed to reducing its debt and leverage to sustainably below 3 (from 3.1 at Q3 end) and has authorized a $500 million share buyback to be executed opportunistically.
- The company will share its Q4 performance and 2026 guidance on February 11th.
Jan 14, 2026, 4:15 PM
Quarterly earnings call transcripts for Avantor.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more